EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study

Ying-Ying Han, Lin Zhou, Yun-Lian Hu, Xiang-Wu Ding, Hui Long, Fei Liu, Ming Xu, Zhen-Yu Zhang, Shuang-Ling Li, Qiu-Yan Wang, Cheng-Xia Su, Yan Chen und 3 weitere

Journal of Gastroenterology · 2023

DOI: 10.1007/s00535-023-02042-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology, 2023. Verfasst von Ying-Ying Han und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 4…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Hainan Provincial Natural Science Foundation of China, Hainan Province Science and Technology Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The application of vonoprazan significantly improved the eradication rate of Helicobacter pylori (H. pylori). This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dual therapy, and to provide a more efficient, safer, and convenient dual regimen for H. pylori infection. METHODS: This was a prospective, open-label, multi-center, randomized controlled study of treatment-naive patients with H. pylori infection. The participants were randomly assigned to the 10-day VA group with vonoprazan 20 mg Bid plus amoxicillin 1 g Tid or the 14-day RA group with rabeprazole 10 mg Tid plus amoxicillin 1 g Tid. The effectiveness, the adverse events, and the patient compliance of the two groups were compared. RESULTS: A total of 690 patients were enrolled. The eradication rates of 10-day VA and 14-day RA dual therapy were 89.3% and 84.9% in intention-to-treat (ITT) analysis (P = 0.088); 90.6% and 85.9% by modified intention-to-treat (mITT) analysis (P = 0.059); 91.4% and 86.6% by per-protocol (PP) analysis (P = 0.047). Non-inferiority was confirmed between the two groups (all P < 0.001). No discernible differences were observed in adverse effects and compliance between groups. Poor compliance reduced the eradication efficacy (P < 0.05). CONCLUSIONS: The 10-day VA dual therapy was non-inferior to the 14-day RA dual therapy for H. pylori treatment-naive patients, which should be given priority in the first-line treatment. The application of vonoprazan reduced treatment course and antibiotic use. Patients' adherence was crucial for the success of eradication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriHumansRabeprazoleProspective StudiesProton Pump InhibitorsClarithromycinDrug Therapy, CombinationAnti-Bacterial AgentsAmoxicillinTreatment OutcomePyrrolesSulfonamides

Stichwörter der Autor:innen

Dual therapyEradication rateHelicobacter pyloriRabeprazoleVonoprazan

Substanzen

RabeprazoleProton Pump InhibitorsClarithromycinAnti-Bacterial AgentsAmoxicillin1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
  • Department of Gastroenterology, Suizhou Central Hospital, Suizhou, China.
  • Department of Gastroenterology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
  • Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China.
  • Department of Gastroenterology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
  • Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

Förderung

  • Hainan Provincial Natural Science Foundation of China
  • Hainan Province Science and Technology Special Fund

Zitieren

APA

Han, Y. Y., Zhou, L., Hu, Y. L., Ding, X. W., Long, H., Liu, F., Xu, M., Zhang, Z. Y., Li, S. L., Wang, Q. Y., Su, C. X., Chen, Y., Chen, J., Lin, Y., & Li, P. Y. (2023). Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-023-02042-2

Vancouver

Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study. Journal of Gastroenterology. 2023. doi:10.1007/s00535-023-02042-2

BibTeX
@article{Han2023,
  author = {Han, Ying-Ying and Zhou, Lin and Hu, Yun-Lian and Ding, Xiang-Wu and Long, Hui and Liu, Fei and Xu, Ming and Zhang, Zhen-Yu and Li, Shuang-Ling and Wang, Qiu-Yan and Su, Cheng-Xia and Chen, Yan and Chen, Jie and Lin, Ya and Li, Pei-Yuan},
  title = {Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study},
  journal = {Journal of Gastroenterology},
  year = {2023},
  doi = {10.1007/s00535-023-02042-2}
}
Kostenlos starten →